Balanced proliferation and differentiation of keratinocytes is essential to cutaneous homeostasis and prevention of skin diseases associated with epidermal barrier defects and cancer. In this context, the coordinated activity of specific enzymes and transcription factors define a complex signaling network that regulates keratinocyte maturation toward terminal differentiation.^[@bib1],\ [@bib2]^

The homeobox transcription factor DLX3 has emerged as a key factor in the control of epidermal homeostasis.^[@bib3],\ [@bib4]^ DLX3 is expressed during the calcium (Ca^2+^)-dependent epidermal differentiation process.^[@bib5],\ [@bib6]^ Mice lacking DLX3 in keratinocytes (DLX3cKO) display epidermal hyperplasia accompanied by barrier disruption with associated development of an inflammatory response,^[@bib3]^ while DLX3 ectopic expression in the basal layer promotes premature keratinocyte differentiation and severely affects the skin phenotype.^[@bib5]^ DLX3 is a target of the p53 family member p63 during ectodermal development and is involved in a regulatory feedback loop with p63 which is crucial for the maintenance of the stratified epithelia.^[@bib7],\ [@bib8]^ More recently, we demonstrated that DLX3 exerts cell cycle regulatory activity in the epidermis by cooperating with the tumor suppressor p53 and is potentially associated with cutaneous squamous cell carcinoma (cSCC) development by controlling p53 and p63 target genes in keratinocytes.^[@bib4]^ However, the specific signaling pathways regulating DLX3 expression during keratinocyte differentiation remains to be fully determined.

In skin, protein kinase C (PKC) signaling is implicated in several pathways leading to epidermal differentiation,^[@bib9]^ with the identification of specific transcriptional PKC effectors in keratinocytes, such as the AP1 complex^[@bib10]^ and other recently determined.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ Among the PKC isozymes, PKC*α* is activated in response to differentiation and pro-inflammatory stimuli, such as calcium or 12-*O*-tetradecanoyl-phorbol-13-acetate (TPA),^[@bib9]^ and acts by inhibiting early differentiation marker expression in favor of late differentiation markers.^[@bib15]^ We previously showed that PKC isoforms are able to phosphorylate DLX3 protein *in vitro*, primarily by PKC*α*.^[@bib16]^ DLX3 protein was phosphorylated in nuclear extracts of mouse keratinocytes and this phosphorylation was inhibited by the PKC inhibitor GF109203X, indicating that DLX3 protein could be potentially phosphorylated by PKC *in vivo*. The phosphorylation event of the DLX3 full-length protein by PKC altered its DNA binding activity.^[@bib16]^

Herein we provide evidence of a robust DLX3--PKC*α* axis in keratinocytes, where PKC*α* also directly regulates DLX3 expression. Gene expression profiles associated with DLX3 epidermal loss, as well as the DLX3cKO skin phenotype, are partially reversed by PKC activity inhibition, emphasizing the functional relevance of the DLX3--PKC-dependent signaling in skin homeostasis. Moreover, we identified a DLX3-dependent, PKC-independent gene signature that is transcriptionally modulated in response to epidermal differentiation.

Results
=======

DLX3 is a downstream effector of PKC*α* activity
------------------------------------------------

DLX3 expression is Ca^2+^ dependent in human and mouse epidermis and crucial for cell cycle exit and differentiation of keratinocytes.^[@bib4],\ [@bib6]^ To determine the signaling mechanisms involved in the induction of DLX3 expression by Ca^2+^ in keratinocytes, we assessed whether this expression was dependent on PKC activity. We demonstrated that Ca^2+^ treatment and TPA, a direct PKC activator, increased DLX3 mRNA ([Figure 1a](#fig1){ref-type="fig"}) in cultured primary keratinocytes. Conversely, PKC inhibition by GF109203X (hereafter referred to as GF) reduced the Ca^2+^-induced DLX3 mRNA levels, as well as the expression of the late differentiation markers loricrin and filaggrin, and of the cell cycle inhibitor and DLX3 target, p21 ([Figure 1b](#fig1){ref-type="fig"} and [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Among the epidermal-specific PKC isoforms, the activation of PKC*α* is Ca^2+^-regulated during epidermal differentiation.^[@bib15]^ We demonstrated that the overexpression and activation of PKC*α*, but not PKC*δ* or *ɛ*, induced DLX3 expression ([Figure 1c](#fig1){ref-type="fig"}), while DLX3 transcription was specifically reduced by PKC*α* silencing either in proliferative or in differentiating conditions ([Figure 1d](#fig1){ref-type="fig"}). In contrast, DLX3 mRNA levels significantly increased by PKC*δ* and PKC*ɛ* silencing, with PKC*δ* silencing detected only under high-Ca^2+^ differentiating conditions ([Supplementary Figure S1c](#sup1){ref-type="supplementary-material"}). This effect could be potentially associated with the roles of PKC*ɛ* and PKC*δ* in keratinocyte proliferation and differentiation^[@bib17],\ [@bib18]^ through a mechanism that remains to be characterized.

To evaluate the effect of PKC*α* activation by TPA on DLX3 transcriptional activity, luciferase reporter assays were performed utilizing PAM-TetOn-V5DLX3/GFP cells that are an immortalized murine keratinocyte cell line that express DLX3 upon addition of doxycycline (Dox).^[@bib19]^ PAM-TetOn-V5DLX3/GFP cells were transfected with a Firefly luciferase reporter construct pGL3-3xDLX3, which contains three concatenated canonical DLX3 binding sites.^[@bib19]^ Cells were grown with or without Dox for 24 h to induce DLX3 expression, and with DMSO or TPA. Significantly higher reporter activity was observed in cells treated with Dox in addition to TPA ([Figure 1e](#fig1){ref-type="fig"}). No significant difference was found when there was no addition of Dox. These results confirm that the induction of DLX3 transcription is directly dependent on PKC*α* activation in keratinocytes *in vitro* and support that DLX3 transcriptional activity is also PKC dependent.

To determine the biological processes associated with PKC*α*-DLX3 signaling, we performed a global transcriptome analysis by DAVID Functional Annotation tool (<https://david.ncifcrf.gov>) of cultured keratinocytes after PKC*α* siRNA and subsequent TPA treatment for 24 h. Gene Ontology (GO) term analysis shows that PKC*α* silencing, and the consequent DLX3 downregulation, leads to a significant enrichment in Regulation of transcription, Keratinocyte differentiation, Phosphorylation and Cell-adhesion Biological Process (BP) terms ([Supplementary Figure S1d](#sup1){ref-type="supplementary-material"}). When cells are TPA treated to induce PKC activation, PKC*α* silencing results in a significant enrichment in Immune response, T-cell chemotaxis, angiogenesis and negative regulation of cell proliferation GO BP terms ([Supplementary Figure S1d](#sup1){ref-type="supplementary-material"}). Interestingly, the marked induction of differentiation (Lce and Sprr late differentiation-associated genes) and inflammation related genes was substantially diminished with PKC*α* siRNA in the presence of TPA ([Figure 1f](#fig1){ref-type="fig"}). Moreover, by comparing genes downregulated in DMSO PKC*α* siRNA *versus* DMSO control siRNA treated cells, we found an enrichment in genes significantly related to protein kinase signaling and cell adhesion ([Supplementary Figure S1e](#sup1){ref-type="supplementary-material"}). Globally, these results confirm the relevance of PKC*α* signaling in keratinocyte differentiation and its contribution to the TPA-induced inflammatory response.^[@bib20]^ These results also support the existence of a PKC*α*--DLX3 axis, which is involved in the regulation of epidermal differentiation by the modulation of PKC signaling and in the regulation of cutaneous homeostasis.

Our previous work demonstrated that PKC isoforms, primarily PKCα, phosphorylate recombinant DLX3 protein *in vitro*.^[@bib16]^ Herein, we demonstrated that DLX3 protein levels are upregulated by PKC activation, either by calcium or by TPA treatment in primary cultured keratinocytes ([Supplementary Figure S2a](#sup1){ref-type="supplementary-material"}). The analysis of DLX3 phosphorylation by the use of Phos-tag acrylamide technology (Wako Pure Chemical Industries, Ltd, Richmond, VA, USA) on keratinocytes transduced with the Adeno-DLX3 expression vector and then treated with TPA confirmed that DLX3 protein is phosphorylated at 1-h post TPA treatment in the absence of protein phosphatase inhibitor ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

The biological relevance of the PKC*α*--DLX3 connection was tested *in vivo* using an epidermal-targeted, TPA-inducible K5-PKC*α* transgenic mouse model.^[@bib20]^ We found a significant increase in DLX3-expressing cells, as well as higher loricrin expression, in TPA-treated transgenic epidermis ([Figures 2a and b](#fig2){ref-type="fig"}). Cultured TPA-treated K5-PKC*α* keratinocytes displayed DLX3 mRNA induction 6 h after treatment ([Figure 2c](#fig2){ref-type="fig"}), which is preceded by the PKC effector c-Fos at 1 h post TPA treatment. The temporal upregulation of c-Fos expression preceding DLX3 was also confirmed by cycloheximide (CHX) treatment of keratinocytes in a time course experiment ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

Increased AP1 activity is associated with PKC*α* activation and its inhibition prevents TPA-dependent cell death of K5-PKC*α* keratinocytes.^[@bib20]^ Keratinocytes transduced with a dominant negative to AP1 activation (AFOS) in proliferative conditions (0.05 mM Ca^2+^) showed significantly increased DLX3 expression ([Figure 2d](#fig2){ref-type="fig"}), leading to the hypothesis that basal (non TPA driven) AP1 activity is negatively regulating Dlx3 mRNA expression. Altogether, these results support that DLX3 expression requires PKC*α* activation and is a downstream target and effector of PKC*α* signaling in skin.

The DLX3--PKC interplay control of epidermal homeostasis
--------------------------------------------------------

To functionally evaluate the facets of DLX3 and PKC*α* axis, we used TPA topical application to activate PKC in a mouse model with DLX3 epidermal deletion (K14Cre;DLX3^Kin/flox^; hereafter referred as DLX3cKO ^3^) and in WT skin ([Figure 3a](#fig3){ref-type="fig"}). TPA treatment led to heightened hyperplasia and hyperkeratosis with significantly increased epidermal thickness and dermal cell infiltration in the DLX3cKO skin when compared with untreated DLX3cKO or TPA-treated WT skin ([Figure 3b](#fig3){ref-type="fig"}).

Analogous to the results obtained with the K5-PKC*α* transgenic mouse model ([Figure 2a](#fig2){ref-type="fig"}), treatment with TPA strongly increased the number of DLX3-expressing cells in WT skin ([Figure 3c](#fig3){ref-type="fig"}). Increased cell proliferation, determined by higher number of Ki-67-positive cells, was assessed for acetone (vehicle) and TPA-treated DLX3cKO epidermis when compared with WT in the same conditions ([Figure 3d](#fig3){ref-type="fig"}). Moreover, immunohistochemical analysis of PKC*α* phosphorylation in acetone and TPA-treated WT and DLX3cKO skin showed heightened detection of p-PKC*α* in untreated DLX3cKO epidermis as well as in the differentiated compartment of the TPA-treated DLX3cKO epidermis when compared with WT ([Figure 3e](#fig3){ref-type="fig"}).

A global transcriptome analysis by DAVID Functional Annotation tool, of acetone and TPA-treated DLX3cKO or WT skin revealed that TPA treatment in a DLX3-ablated epidermis leads to the upregulation of gene expression profiles related to epidermal barrier disruption, cytokines/chemokines and antimicrobial peptides ([Figure 4a](#fig4){ref-type="fig"}). Particularly relevant in the TPA-treated DLX3cKO skin is the upregulation of expression of a subset of Lce, Sprr, S100 and kallikrein genes, as well as beta-defensin, lipocalin-2, Krt6b and Krt16 genes, which are strongly linked to epidermal hyperproliferative inflammatory diseases.^[@bib21],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25]^

Given that the epidermal deletion of DLX3 is linked to an IL-17-associated skin inflammation,^[@bib3]^ we analyzed leukocyte accumulation in the dermis by staining for CD45 in TPA-treated DLX3cKO skin. CD45-positive cell count was determined by measuring the total labeled particles and area, as described in Materials and Methods. We found that TPA treatment further increased the detection of CD45-positive cells in DLX3cKO skin compared with the TPA-treated WT or untreated DLX3cKO ([Figure 4b](#fig4){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). We also assessed the inflammatory response of DLX3-null keratinocytes in culture by treatment with TPA and analysis of cytokine release utilizing a profiler array. *Z*-score evaluation of the cytokine concentrations confirmed a correlation with the release of the inflammatory mediators associated with leukocyte chemotaxis^[@bib26],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30]^ in TPA-treated DLX3cKO keratinocytes when compared with DMSO (control vehicle)-treated DLX3cKO cells, or TPA and DMSO-treated WT cells ([Figure 4c](#fig4){ref-type="fig"}).

Transcriptome analysis of TPA-treated DLX3cKO *versus* WT cultured keratinocytes revealed significant enrichment in epidermal differentiation, keratinization, epidermal development and immune response GO Biological Process terms ([Figure 4d](#fig4){ref-type="fig"}), with differential expression of the epidermal differentiation-related genes such as Sprr, Tgm3 and Lcn2 ([Figure 4e](#fig4){ref-type="fig"}). These results correlate with those obtained in TPA-treated keratinocytes in culture ([Figure 1f](#fig1){ref-type="fig"}) and in TPA-treated DLX3cKO skin (epidermal barrier disruption and antimicrobial peptides; [Figure 4a](#fig4){ref-type="fig"}). Interestingly, the expression of Loricrin, which is a downstream target of PKC*α*-dependent differentiation,^[@bib31]^ was specifically reduced in DLX3-null keratinocytes compared with WT in the presence of PKC activation. These data support a functional and integrated DLX3--PKC pathway required for proper transcriptional control of keratinocyte proliferation and differentiation, as well as a homeostatic maintenance of the epidermal barrier.

PKC inhibition restores a more normal phenotype to DLX3cKO epidermis
--------------------------------------------------------------------

Next, we investigated the effect of PKC inhibition in DLX3cKO epidermis by treatment with GF following the same protocol used for TPA treatments ([Figure 5a](#fig5){ref-type="fig"}). GF application significantly decreased epidermal thickness compared with the untreated mice ([Figure 5b](#fig5){ref-type="fig"}), with decreased hyperplasia and hyperkeratosis and a reduction of Ki-67-positive cells ([Figure 5c](#fig5){ref-type="fig"}). A reduced number of DLX3-positive cells in GF-treated WT skin was detected ([Figure 5d](#fig5){ref-type="fig"}). The epidermal hyperplasia in DLX3cKO skin was also normalized by the specific PKC*α* inhibitor Gö6976 ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

The inhibition of PKC*α* phosphorylation after GF treatment was confirmed by immunohistochemistry ([Figure 5e](#fig5){ref-type="fig"}). In addition, the inhibition of PKC normalizes the expression of filaggrin and recovers the expression of keratin 10 in GF-treated DLX3cKO epidermis ([Figure 5f](#fig5){ref-type="fig"}) underlining the role of activated PKC*α* in DLX3cKO epidermis. Moreover, we found increased mRNA levels for p53, p21 and CcnE1 in GF-treated DLX3cKO skin compared with vehicle-treated skin ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}), suggesting a potential cell cycle rescue in DLX3cKO skin.

ERK is a well-known downstream effector of PKC*α* activity in keratinocytes^[@bib32]^ and we previously reported that loss of DLX3 in cultured keratinocytes is associated with activation of ERK.^[@bib4]^ Here, we corroborated this effect *in vivo*, and showed that DLX3cKO epidermis presented higher level of the phosphorylated ERK and that it decreased in GF-treated DLX3cKO skin, with total ERK remaining unchanged ([Figure 5g](#fig5){ref-type="fig"}). Altogether, these results support that PKC*α* signaling is connected with DLX3-dependent regulation of epidermal growth and absence of DLX3 function in keratinocytes causes a PKC*α*-dependent alteration of the epidermal phenotype.

We conducted a global transcriptomic analysis of the GF-treated and untreated DLX3cKO and WT skin and found that relative to untreated DLX3cKO skin, GF treatment downregulated a subset of barrier-associated markers, cytokine/chemokines and antimicrobial peptides ([Figure 6a](#fig6){ref-type="fig"}), previously found to be affected by activated PKC*α* in DLX3cKO skin ([Figure 4a](#fig4){ref-type="fig"}). We show that GF treatment decreased the detection of CD45-positive cells in DLX3cKO skin compared with the GF-treated WT or untreated DLX3cKO ([Figure 6b](#fig6){ref-type="fig"} and [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}).

GF treatment also specifically decreased the level of cytokines released by DLX3cKO cells *in vitro* ([Figure 6c](#fig6){ref-type="fig"}). Interestingly, the greater IL-1*α* release by TPA-treated DLX3-null keratinocytes compared with WT in the same condition was not inhibited by GF, indicating that this mechanism is independent of the PKC--DLX3 axis, but is associated with the DLX3-null keratinocyte phenotype.^[@bib4]^ In contrast, the release of G-CSF, KC, CCL3 and CCL4 was specifically inhibited in the DLX3cKO cells and the secretion of GM-CSF, RANTES and MCP-1 was more comparable to the WT level after GF treatment ([Figure 6c](#fig6){ref-type="fig"}). Other cytokines such as Eotaxin and IL-12p70 showed upregulation after GF treatment in a process that might involve signals distinct from the PKC--DLX3 pathway.

DLX3-dependent control of epidermal homeostasis by PKC-independent signaling
----------------------------------------------------------------------------

The analysis of differentially expressed genes between DLX3cKO and WT skin, both treated with TPA or GF, or untreated, allowed the identification of specific signaling pathways within cutaneous homeostasis whose regulation is DLX3 dependent and not linked to PKC activity ([Figure 7a](#fig7){ref-type="fig"}).

In DLX3-null skin, we found that the expression level of Msx1, Rara, Shh, Lef1 and Foxe1 (Regulation of transcription; [Figure 7a](#fig7){ref-type="fig"}) was upregulated and PKC inhibition did not significantly modulate their expression level ([Figure 7a](#fig7){ref-type="fig"}, upper left heatmap). These genes are expressed during epidermal differentiation, target-specific aspects of keratinocyte maturation and hair follicle development.^[@bib33],\ [@bib34],\ [@bib35]^ DLX3 is expressed during hair morphogenesis in the hair matrix at the beginning of hair shaft differentiation and its deletion results in impaired expression of hair keratins leading to alopecia.^[@bib36]^ The modulation of a subset of genes, for example, Lef1, Shh, Msx1, Foxe1 that are regulated by DLX3 independently of PKC, could also be attributed to DLX3 function in keratinocytes of the hair follicle.^[@bib36]^ DLX3 function was also linked to the Wnt signaling pathway, with all of the genes included in this pathway being significantly upregulated in DLX3cKO skin. Wnt signaling pathway showed little alteration after GF treatment ([Figure 7a](#fig7){ref-type="fig"}, upper right heatmaps).

Transcripts for genes encoding for protein phosphatases^[@bib37]^ and adhesion molecules, such as integrins and CAM^[@bib38],\ [@bib39]^ ([Figure 7a](#fig7){ref-type="fig"}, lower heatmaps) were decreased in the absence of DLX3 and expression was not affected by PKC inhibition. Remarkably, the dual specificity phosphatases, which present downregulation during cSCC progression,^[@bib37]^ are downregulated in DLX3-null cells.

TPA treatment induces skin inflammation and hyperproliferation through different mechanisms.^[@bib9]^ In order to define what aspects of these processes are PKC dependent in DLX3cKO skin, we performed treatments with GF prior to TPA application (hereafter referred to as GF-TPA treatment), following the same protocol used in [Figure 3a](#fig3){ref-type="fig"}. RNA-seq analysis determined the upregulated and downregulated genes in acetone (control vehicle), TPA or GF-TPA-treated DLX3cKO skin, which were normalized against WT. Unique and common genes were determined by Venny comparative tool (<http://bioinfogp.cnb.csic.es/tools/venny>) and each list was analyzed with DAVID Functional Annotation tool to obtain GO BP term enrichment. When PKC signaling is inhibited in DLX3cKO skin, there is a subset of specific genes involved in cell cycle (cell cycle phase, M phase, cell division) ([Figure 7b](#fig7){ref-type="fig"}, left panel) that is upregulated by TPA, while genes within regulation of the immune system process and regulation of leukocyte-mediated immunity clusters were downregulated in the same conditions ([Figure 7b](#fig7){ref-type="fig"}, right panel). Therefore, PKC activation in DLX3cKO skin is linked to the TPA-induced phenotype. Interestingly, the analysis of the genes common between GF-TPA and TPA treatments corroborated that the regulation of transcription, the intracellular signaling cascade, cell adhesion and the regulation of phosphate metabolic processes are DLX3 -dependent signaling pathways.

In order to determine potential direct targets of DLX3 regulation, we performed chromatin immunoprecipitation sequencing (ChIP-seq) analysis on epidermal suprabasal cells. ChIP-seq analysis of DLX3 and H3K4me3 DNA binding domains identified DLX3-bound promoter regions of genes involved in cell cycle regulation during differentiation, such as Ccnd1, Ccne1;^[@bib41],\ [@bib42]^ and epidermal structure, such as Clic4, Dsp, Evpl, Fabp5,^[@bib43],\ [@bib44],\ [@bib45],\ [@bib46]^ and transcription factors such as Grhl3, Klf4, Msx2 and Notch1^[@bib47],\ [@bib48],\ [@bib49],\ [@bib50]^ ([Figure 8](#fig8){ref-type="fig"}). Together with the transcriptomic analysis, the ChIP-seq analysis of DLX3 and H4K4m3 binding supports a potential DLX3-dependent transcriptional regulation of these genes during epidermal differentiation.

Discussion
==========

The homeobox transcription factor DLX3 is well known for its implication in developmental regulation of several tissues. ^[@bib51],\ [@bib52]^ However, its role as a \'switch molecule\' regulating the balance between differentiation and proliferation of keratinocytes in epidermis has recently emerged.^[@bib4]^ DLX3 is expressed in the nuclei of the suprabasal epidermal cells of healthy skin.^[@bib3]^ In contrast, in skin disorders associated with altered differentiation and barrier defects, such as atopic dermatitis or psoriasis, and squamous cell carcinoma, its expression pattern is altered with a higher number of DLX3-positive cells in atopic dermatitis compared with no detectable expression in psoriasis and cSCC.^[@bib3],\ [@bib4]^ These findings and observations indicate that nuclear suprabasal DLX3 expression is strongly associated with the maintenance of epidermal homeostasis, by potentially regulating multiple pathways in skin either directly or indirectly through other transcription factors. In fact, we previously showed that a conditional epidermal deletion of DLX3 in mouse skin induces skin phenotype alterations with epidermal hyperplasia, barrier defects and the development of an IL-17 dependent inflammatory response,^[@bib3]^ overall supporting the relevance of the DLX3 signaling pathways in epidermal homeostasis.

We report that DLX3 is a downstream signaling effector of PKC and highlight the importance of a functional PKC--DLX3 axis during epidermal differentiation to preserve the cutaneous homeostatic balance. Previous work demonstrates that PKC isoforms are able to interact and phosphorylate DLX3 *in vitro*. Our results here confirm this data and show a direct link between PKC*α* and DLX3, establishing DLX3 as a target of PKC*α* signaling. Furthermore, while PKC*α* regulates DLX3, there is heightened detection of p-PKC*α* in DLX3cKO epidermis evoking a potential negative feedback loop that regulates PKC*α* activity. We found no putative DLX3 binding site in the PKC*α* promoter and no significant variation of PKC*α* mRNA expression in any of the data set profiles analyzed ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Nevertheless, p-PKC*α* is elevated in epidermis genetically deleted of DLX3 and the hyperproliferative response to TPA is increased, suggesting that the homeobox protein indirectly regulates the activity in the pathway, possibly through an effect on reduced phosphatase expression ([Figure 7a](#fig7){ref-type="fig"}). The reduction in phosphatase activity could also explain the increase in p-ERK previously reported in the DLX3cKO epidermis.^[@bib4]^

Increasing PKC*α* activity in skin is linked to altered terminal differentiation and intraepidermal inflammation.^[@bib20]^ Here we demonstrate that, in absence of DLX3, the expression of late differentiation markers is favored and that recruitment of inflammatory cells, as well as release of the PKC*α*-dependent inflammatory mediators, increased. Taken together, these results indicate that altered PKC signaling is at least partially determinant in the development of the DLX3cKO phenotype.

Therefore, we propose a model ([Figure 9](#fig9){ref-type="fig"}) where in response to differentiation or pro-inflammatory stimuli, such as calcium or TPA, DLX3 partially regulates the expression of a PKC-dependent gene signature characterized by epidermal differentiation and barrier formation defects, inflammatory mediator release, antimicrobial peptides and cell cycle. However, other pathways related to the control of epidermal homeostasis (i.e. regulation of transcription, Wnt signaling, phosphatase activity and cell adhesion) result from DLX3-dependent, PKC-independent mechanisms and are directly or indirectly mediated by still unknown signaling intermediates. Other signaling pathways have been determined to be indispensable for keratinocyte differentiation and barrier function.^[@bib53],\ [@bib54]^ It remains to be determined which other DLX3-dependent signaling pathway will prove to be essential in epidermal homeostasis. Taken together, the work presented here reveals a DLX3--PKC axis in the regulation of keratinocyte proliferation and differentiation balance.

Materials and methods
=====================

Generation and analysis of transgenic mice
------------------------------------------

Mouse experiments were performed under a protocol approved by the National Cancer Institute (NCI) and the NIAMS Animal Care and Use Committee. DLX3cKO mice were generated and genotyped as previously reported.^[@bib36]^ TPA-inducible K5-PKC*α* mice were generated as previously reported.^[@bib20]^ Tissue was dissected 3 days after TPA treatment (2 *μ*g/200 *μ*l acetone) for IHC. Acetone (200*μ*l)-treated mice were used as a control.

For GF109203X, Gö6976 and TPA treatments, 9 weeks WT and DLX3cKO mice were shaved one day prior to topical application. Mice were topically treated with TPA (5 *μ*g/100 *μ*l acetone), GF (50 *μ*g/100 *μ*l), or acetone (100 *μ*l) every 2 days for 6 days for a total of three treatments. Tissues were dissected the day after the last treatment for IHC, RNA or protein extraction.

Primary keratinocyte culture, cell culture and transduction
-----------------------------------------------------------

Normal human epidermal keratinocytes (NHEK) were obtained from surgically resected human foreskins from the NIH Clinical Center, Dermatology Branch, after provision of written consent. NHEK were isolated and maintained in KGM (Lonza, Walkersville, MD, USA), with Ca^2+^ concentration of 0.05 mM (proliferating media). To induce keratinocyte differentiation, a final concentration of 1.8 mM Ca^2+^ was used. Primary murine keratinocytes (PMK) were isolated from TPA-inducible K5-PKC*α*, DLX3cKO and WT mice as previously described.^[@bib55]^ PMK were cultured in S-MEM (Gibco, Waltham, MA, USA) with 8% fetal bovine serum (FBS; Atlanta Bio, Flowery Branch, GA, USA), 1% antibiotic (PSA; Sigma, St. Louis, MO, USA), with Ca^2+^ concentration of 0.05 mM (proliferating media). To induce keratinocyte differentiation, a final concentration of 0.12 mM Ca^2+^ was used. For gene and protein expression studies, cells were transfected with scramble siRNA or PKC*α* siRNA (50 nM; Qiagen, Hilden, Germany); transduced with Null or PKC*α*, PKC*δ*, PKC*ɛ* adenoviruses (5 MOI) or transduced with Control or AFOS adenoviruses (5 MOI). Adenoviral particles were generated as previously described.^[@bib56]^

Reporter assays
---------------

To determine the transcriptional activity, a synthetic oligonucleotide containing three tandem copies of the DLX3 responsive element (DRE; GCGATAATTGCGGCGATAATTGCGGCGATAATTGCG)^[@bib57]^ followed by the hamster sarcoma virus thymidine kinase proximal promoter region was inserted into the pGL3-basic vector (pGL3-3XDRE) driving a Firefly luciferase reporter cassette. PAM-Tet-ON DLX3 cells were transiently co-transfected with the reporter construct and the pRL-TK vector (*Renilla* luciferase used for normalization). Twenty-four hours after transfection, relative luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA).

Chemical treatments *in vitro*
------------------------------

Cells were treated with DMSO (control), TPA (5 ng/ml) (Sigma) or GF109203X (10 *μ*M) (Calbiochem, San Diego, CA, USA) and harvested at different time points according to the specific experiment.

Western blot analysis
---------------------

Lysates of cells and tissues were prepared in SDS sample buffer (60 mM Tris-HCl at pH 6.8, 10% glycerol, 2% SDS and 5% 2-mercaptoethanol). Equal amounts of lysate proteins (25 *μ*g) were separated on 4--12% SDS-PAGE gels, transferred to PVDF membranes (Invitrogen, Carlsbad, CA, USA), and incubated with primary antibodies specific to DLX3 (Epitomics, Burlingame, CA, USA), PKC*α* (Sigma), P-ERK (Cell Signaling, Danvers, MA, USA), T-ERK (Cell Signaling), Vinculin (Sigma) and *β*-actin (Sigma). Blots were then rinsed in TBST and further incubated in peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies, respectively. Proteins were visualized using an ECL detection system (Pierce Biotech, Waltham, MA, USA) and exposed to film. All experiments were repeated in triplicate.

Histology and immunohistochemistry
----------------------------------

For histological and immunohistochemical analysis, tissues were fixed with 4% PFA and embedded in paraffin. Five micrometer sections were prepared for specific staining. Each section was incubated overnight at 4 °C with the primary antibodies which included: DLX3 (Epitomics), P-PKC*α* (Abcam, Cambridge, UK), KRT5 and KRT10 (Covance, Princeton, NJ, USA), Filaggrin (Covance), Ki-67 (BD Bioscience, San Jose, CA, USA) and CD45 (BD Biosciences). The Alexa Fluor 488 and 555-conjugated were used as secondary antibodies. Epidermal thickness was determined by ImageJ software analysis throughout each image. DLX3 and CD45-positive cells were determined by ImageJ software through the use of the cell counter function or by integrating particle analysis with the measure of the labeled area, respectively.

RNA extraction and qRT-PCR
--------------------------

Total RNA was extracted from cells and tissues using RNeasy kit (Qiagen) according to the maufacturer\'s instructions. cDNA was prepared using the ImProm-II Reverse Transcription System (Promega). For each gene qRT-PCR analysis was done in triplicate using the iQSYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The following genes were analyzed: DLX3, p21, Flg (Filaggrin) and Lor (Loricrin), c-Fos, p53, CCNE1. Primer sequences used in qRT-PCR are indicated in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. Relative expression was normalized against the housekeeping gene RPLPO. Fold changes were calculated by the Ct method as previously described.^[@bib4]^

Cytokine array
--------------

A Luminex Cytokine Array (Bio-Rad) was used to determine cytokine release by cells. Briefly, WT and DLX3cKO cells were treated with TPA or GF for 24 h before supernatant was collected for analysis. DMSO was used as a control. Cytokine concentration in the supernatant was determined according to the manufacturer\'s protocol.

Expression profiling
--------------------

RNA sequencing was performed in the NIAMS Genome Core Facility at the NIH. Mondrian SP was used for the cDNA library preparation and the HiSeq 2000 was used for sequencing. Significantly affected genes (*P*\<0.05 and fold change\>1.5) were determined on ANOVA.

Computational analysis
----------------------

RNA-Seq expression fold changes were calculated using Partek Genomics Suite (<http://www.partek.com>). Pathway enrichment of significantly modulated genes (*q*\<0.05 and Max RPKM\>0) was generated through DAVID Functional Annotation Tools ([https://**david**.ncifcrf.gov/](https://david.ncifcrf.gov/)). All heatmaps were generated with the R programming environment using Wards method with Euclidean distance (<http://www.r-project.org/>).

Suprabasal epidermal cells ChIP-seq analysis
--------------------------------------------

Suprabasal epidermal cells were obtained after epidermis--dermis separation of neonatal skins by Percoll-gradient.^[@bib58]^ Briefly, the epidermal cells were resuspended in a mix of 50% Percoll, 40% high calcium media and 10% 10 × PBS and then centrifugated to collect the suprabasal fraction. Chromatin crosslinking of the isolated suprabasal keratinocytes was performed with formaldehyde 1% for 10 min at 37C, followed by neutralization with 125 mM glycine. Fixed cells were suspended in shearing buffer (50 mM Tris at pH 7.6 and 0.2% Triton X-100) and proteinase inhibitors, and then sonicated using Bioruptor (Diagenode Inc., Denville, NJ, USA). Detergents (1% Triton X-100, 0.1% SDS and 0.1% sodium deoxycholate (DOC) and 0.1 mM EDTA solution were added and the suspension was centrifuged at 13 000 r.p.m. for 10 min to collect the supernatant. After overnight incubation of supernatant with protein A Dynabeads (Thermo Fisher Scientific, Waltham, MA, USA) and either (Anti-DLX3 (Abcam ab178428) or Anti-H3K4me3 (Diagenode C15410003), the beads were washed with a series of washing buffer solutions (two times for each buffer): RIPA buffer, RIPA buffer containing 0.3M NaCl, LiCl buffer containing 0.5% NP40 and 0.5% NaDOC, Tris-EDTA buffer containing 0.2% Triton-X-100 and Tris-EDTA. DNA fragments were obtained by incubation for 4 h at 65C with Tris-EDTA solution containing 0.3% SDS and 1 mg/ml proteinase K. The DNA Library was prepared after fragment purifications and sequenced using Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). MACS 1.4 was used for peak calling and Integrative Genomics Viewer and PAPST was used to visualize the peak regions from Transcription Start Sites (TSS).

Statistical analysis
--------------------

The data were analyzed by Prism Software (GraphPad Software, Inc, La Jolla, CA, USA) and significance was assessed by the Student\'s *t*-test. For all experiments with error bars, standard deviations were calculated to indicate variations within each experiment and data, and values represent mean±standard deviation of mean. *P*\<0.05, *P*\<0.01, *P*\<0.001, *P*\<0.0001 were considered significant.
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![PKC*α* triggers DLX3 expression in keratinocytes. (**a**) DLX3 expression in primary keratinocytes maintained in proliferative (0.05 mM Ca^2+^) and differentiating media (0.12 mM Ca^2+^) or treated with TPA for 24 h. (**b**) DLX3 and Loricrin expression in primary keratinocytes maintained in 0.12 mM Ca^2+^ media +/− GF109203X at 24 h. (**c**) Relative expression level of DLX3 in primary keratinocytes transduced with Adeno-Null or Adeno-PKC*α*, *δ* or *ɛ* viruses and treated with TPA for 1 h in 0.05 mM Ca^2+^ media. Bottom panel, western blot performed with protein extracts from cells transduced with Ad-Null and Adeno-PKC*α*, with or without TPA treatment. (**d**) DLX3 expression in primary keratinocytes transfected with PKC*α* siRNA at 48 h in 0.05 mM Ca^2+^ or 0.12 mM Ca^2+^ media. Bottom panel, western blot performed with protein extracts from cells transduced with PKC*α* siRNA. (**e**) Luciferase reporter assays were performed in PAM212-DLX3 tet-on cells transfected with a Firefly luciferase reporter construct containing the concatemerized canonical DLX3 binding. Cells were grown with or without Doxycyclin for 24 h to induce DLX3 expression. Significantly higher reporter activity was observed in cells treated with Dox after 6 h of TPA treatment. For all panels, \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001 and the results are mean ± SD of three experiments. (**f**) Heatmaps of differentially expressed mRNAs in PKC*α versus* Scramble siRNA treated keratinocytes after TPA or DMSO (control) stimulus for differentiation (left) or inflammation (right) clusters. Expression values are colored based on their *z*-score after normalization across treatments](cdd20175f1){#fig1}

![DLX3 expression is upregulated by PKC*α* activation *in vivo*. (**a**) Immunohistochemical staining of TPA-treated WT and K5-PKC*α* transgenic skin with antibodies against KRT5 and DLX3 or KRT5 and Loricrin (LOR). Scale bar, 20 *μ*m. (**b**) Bar graph showing the number of DLX3-positive cells normalized *versus* the nuclei in WT and K5-PKCα skin treated with TPA or acetone (control). DLX3-positive cells and the number of nuclei in each section were determined by ImageJ software analysis of the labeled particles. Data are presented as mean±S.D. of three different areas from three independent mice for each condition. \*\*\**P*\<0.001. (**c**) Relative expression level of DLX3 and c-Fos in WT or K5-PKC*α* primary keratinocytes treated with TPA at 1 and 6 h. (**d**) DLX3 expression level in cultured keratinocytes transduced with Ad-AFOS or Ad-Cntl vectors at 48 h. For all panels: \*\**P*\<0.01, \*\*\**P*\<0.001 and the results are shown as mean±S.D. of three independent experiments](cdd20175f2){#fig2}

![PKC activation exacerbates DLX3cKO epidermal hyperproliferation. (**a**) Schematic representation of TPA treatment of WT or DLX3cKO mice. (**b**) Hematoxylin and eosin staining of TPA-treated WT or DLX3cKO transgenic skin. Scale bar, 20 *μ*m. Epidermal thickness was measured and data are presented as mean±S.D. of three different areas from three different mice for each condition. \*\*\**P*\<0.001. (**c**) Immunohistochemical staining of TPA-treated WT and DLX3cKO transgenic skin with antibodies against KRT5 and DLX3. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. Bottom panel, bar graph showing the number of DLX3-positive cells normalized *versus* the nuclei in WT and DLX3cKO skin treated with TPA or acetone (control). DLX3-positive cells and the number of nuclei in each section were determined by ImageJ software analysis of the labeled particles. Data are presented as mean±S.D. of three different areas from three independent mice for each condition. \*\**P*\<0.01. (**d**) Immunohistochemical staining of TPA-treated WT and DLX3cKO transgenic skin with antibodies against Ki-67. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. Bottom panel, Ki-67-positive cell count in WT and DLX3cKO epidermis +/− TPA. Data are presented as mean±S.D. of three different areas from three different mice for each condition. (**e**) Immunohistochemical staining of TPA-treated WT and DLX3cKO mice with antibodies against P-PKC*α*. Nuclei were stained with DAPI. Scale bar, 20 *μ*m](cdd20175f3){#fig3}

![PKC activation raises the DLX3cKO epidermal barrier alteration and inflammatory phenotype. (**a**) Heatmaps of differentially expressed mRNAs in WT or DLX3cKO skin treated with TPA or acetone (control) represent the top affected clusters by DAVID functional annotation analysis: epidermal barrier disruption (left), cytokine/chemokine (middle) and antimicrobial peptides (right). Expression values are colored based on their *z*-score after normalization across treatments. (**b**) Immunohistochemical staining of TPA-treated WT and DLX3cKO transgenic skin with antibodies against CD45. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. (**c**) Heatmap of the cytokines released by WT or DLX3cKO keratinocytes after treatment with TPA in culture for 24 h. DMSO was used as a control. Cytokine concentration values are colored based on their *z*-score after normalization across treatments. (**d**) Bar graph showing GO term Biological Process (BP) enrichment by DAVID Functional Annotation tool in DLX3cKO *versus* WT keratinocytes treated with TPA for 36 h. (**e**) Bar graph showing the fold change for keratinocyte differentiation-related genes in TPA-treated DLX3cKO *versus* WT keratinocytes](cdd20175f4){#fig4}

![PKC inhibition partially restores epidermal thickness and keratinocyte proliferation in DLX3cKO skin. (**a**) Schematic representation of GF109203X (GF) treatment of WT or DLX3cKO mice. (**b**) H&E staining of GF-treated WT and DLX3cKO skin. Epidermal thickness was measured and data are presented as mean±S.D. of three different areas from three different mice per condition. (**c**) Immunohistochemical staining of GF-treated WT and DLX3cKO transgenic skin with antibodies against Ki-67. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. Bottom panel, Ki-67-positive cell count in WT and DLX3cKO epidermis +/− GF. Data are presented as mean±S.D. of three different areas from three different mice for each condition. (**d**) Immunohistochemical staining of GF-treated WT and DLX3cKO transgenic skin with antibodies against KRT5 and DLX3. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. Bottom panel, bar graph showing the number of DLX3-positive cells normalized *versus* the nuclei in WT and DLX3cKO skin treated with GF or acetone (control). DLX3-positive cells and the number of nuclei in each section were determined by ImageJ software analysis of the labeled particles. Data are presented as mean±S.D. of three separate areas from three different mice for each condition. \*\*\**P*\<0.001. (**e**) Immunohistochemical staining of GF-treated WT and DLX3cKO mice with antibodies against P-PKC*α* and (**f**) against KRT5 and KRT10 (upper panel) and Filaggrin (lower panel). Nuclei were stained with DAPI. Scale bar, 20 *μ*m. (**g**) Total ERK and phosphor-ERK (P-ERK) expression levels determined by western blot of protein extracts from GF-treated WT and DLX3cKO transgenic skin. GAPDH was used as a loading control](cdd20175f5){#fig5}

![PKC inhibition restores the DLX3cKO epidermal barrier alteration and inflammatory phenotype. (**a**) Heatmaps of differentially expressed mRNAs in WT or DLX3cKO skin treated with GF109203X or acetone (control) related to the top affected clusters by DAVID functional annotation analysis: epidermal barrier disruption (left), cytokine/chemokine (middle) and antimicrobial peptides (right). Expression values are colored based on their *z*-score after normalization across treatments. (**b**) Immunohistochemical staining of GF109203X-treated WT and DLX3cKO transgenic skin with antibodies against CD45. Nuclei were stained with DAPI. Scale bar, 20 *μ*m. Data are presented as mean±S.D. of three different areas from three different mice for each condition. (**c**) Heatmap of the cytokines released by WT or DLX3cKO keratinocytes after treatment with GF109203X in culture for 24 h. DMSO was used as a control. Cytokine concentration values are colored based on their *z*-score after normalization across treatments](cdd20175f6){#fig6}

![DLX3-dependent regulation of epidermal homeostasis-related signaling pathways. (**a**) Heatmaps showing the DLX3-dependent upregulation of the \'Regulation of Transcription\' and \'Wnt Signaling\' pathways between DLX3cKO and WT skin treated with GF109203X or acetone (control). Bottom: Heatmaps showing the DLX3-dependent downregulation of the \'Phosphatase Activity\' and \'Cell Adhesion\' signaling pathways between DLX3cKO and WT skin treated with TPA or GF109203X or acetone (control). Expression values are colored based on their *z*-score after normalization across treatments. (**b**) Schematic representation by Venny diagrams of the significantly upregulated (left) or downregulated (right) genes in DLX3cKO skin after treatment with GF109203X prior to TPA (GF-TPA), TPA or acetone (control). Top significant GO Biological Process (BP) terms are indicated in tables: GF-TPA unique (orange), TPA unique (light blue) and GF-TPA and TPA common (green)](cdd20175f7){#fig7}

![DLX3 transcriptional control of cell cycle and epidermal differentiation. ChIP-seq analysis of DLX3 and H3K4me3 DNA binding domains in suprabasal epidermal keratinocytes, showing DLX3 binding within the promoter regions of genes involved in cell cycle regulation (Ccnd1, Ccne1), epidermal differentiation (Clic4, Dsp, Evpl, Fabp5) and transcription factors (Grhl3, Klf4, Msx2, Notch1). Integrative Genomics Viewer and PAPST^[@bib59]^ were used to visualize the peak regions from Transcription Start Sites (TSS)](cdd20175f8){#fig8}

![PKC--DLX3-dependent control of cutaneous homeostasis. Schematic working model of PKC--DLX3 signaling in keratinocytes displaying that, in response to differentiation or pro-inflammatory stimuli, such as calcium or TPA, DLX3 regulates PKC-dependent gene expression signature associated with barrier defects, inflammatory mediator release, antimicrobial peptides and cell cycle. Independently of PKC, DLX3 is implicated in the transcriptional control of other pathways, such as negative regulation of transcription, Wnt signaling, phosphatase activity and cell adhesion. Globally this signaling is determinant for the maintenance of the cutaneous homeostasis](cdd20175f9){#fig9}
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